These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18294022)

  • 21. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study.
    Philip NS; Dunner DL; Dowd SM; Aaronson ST; Brock DG; Carpenter LL; Demitrack MA; Hovav S; Janicak PG; George MS
    Brain Stimul; 2016; 9(2):251-7. PubMed ID: 26708778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized sham controlled trial of repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex for the treatment of panic disorder with comorbid major depression.
    Mantovani A; Aly M; Dagan Y; Allart A; Lisanby SH
    J Affect Disord; 2013 Jan; 144(1-2):153-9. PubMed ID: 22858212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial.
    Plewnia C; Pasqualetti P; Große S; Schlipf S; Wasserka B; Zwissler B; Fallgatter A
    J Affect Disord; 2014 Mar; 156():219-23. PubMed ID: 24411682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurocognitive Effects of Repetitive Transcranial Magnetic Stimulation With a 2-Coil Device in Treatment-Resistant Major Depressive Disorder.
    Kavanaugh BC; Aaronson ST; Clarke GN; Holtzheimer PE; Johnson CW; McDonald WM; Schneider MB; Carpenter LL
    J ECT; 2018 Dec; 34(4):258-265. PubMed ID: 29613944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Pilot Study of High-Frequency Transcranial Magnetic Stimulation for Bipolar Depression.
    Aaronson ST; Goldwaser EL; Croarkin PE; Geske JR; LeMahieu A; Sklar JH; Kung S
    J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38780536
    [No Abstract]   [Full Text] [Related]  

  • 28. Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder.
    Rosenquist PB; Krystal A; Heart KL; Demitrack MA; McCall WV
    Psychiatry Res; 2013 Jan; 205(1-2):67-73. PubMed ID: 23021320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A sham-controlled trial of the efficacy and safety of twice-daily rTMS in major depression.
    Loo CK; Mitchell PB; McFarquhar TF; Malhi GS; Sachdev PS
    Psychol Med; 2007 Mar; 37(3):341-9. PubMed ID: 17176505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial.
    McGirr A; Van den Eynde F; Tovar-Perdomo S; Fleck MP; Berlim MT
    J Affect Disord; 2015 Mar; 173():216-20. PubMed ID: 25462419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depression (TRMD) Veteran patients: study protocol for a randomized controlled trial.
    Mi Z; Biswas K; Fairchild JK; Davis-Karim A; Phibbs CS; Forman SD; Thase M; Georgette G; Beale T; Pittman D; McNerney MW; Rosen A; Huang GD; George M; Noda A; Yesavage JA
    Trials; 2017 Sep; 18(1):409. PubMed ID: 28865495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression.
    Mantovani A; Pavlicova M; Avery D; Nahas Z; McDonald WM; Wajdik CD; Holtzheimer PE; George MS; Sackeim HA; Lisanby SH
    Depress Anxiety; 2012 Oct; 29(10):883-90. PubMed ID: 22689290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The sertraline versus electrical current therapy for treating depression clinical study (select-TDCS): results of the crossover and follow-up phases.
    Valiengo L; Benseñor IM; Goulart AC; de Oliveira JF; Zanao TA; Boggio PS; Lotufo PA; Fregni F; Brunoni AR
    Depress Anxiety; 2013 Jul; 30(7):646-53. PubMed ID: 23625554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-frequency repetitive transcranial magnetic stimulation in the right prefrontal cortex combined with partial sleep deprivation in treatment-resistant depression: a randomized sham-controlled trial.
    Krstić J; Buzadžić I; Milanović SD; Ilić NV; Pajić S; Ilić TV
    J ECT; 2014 Dec; 30(4):325-31. PubMed ID: 24625704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
    Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
    J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increase of frontal cerebral blood volume during transcranial magnetic stimulation in depression is related to treatment effectiveness: A pilot study with near-infrared spectroscopy.
    Shinba T; Kariya N; Matsuda S; Matsuda H; Obara Y
    Psychiatry Clin Neurosci; 2018 Aug; 72(8):602-610. PubMed ID: 29774621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frontostriatal Connectivity Changes in Major Depressive Disorder After Repetitive Transcranial Magnetic Stimulation: A Randomized Sham-Controlled Study.
    Kang JI; Lee H; Jhung K; Kim KR; An SK; Yoon KJ; Kim SI; Namkoong K; Lee E
    J Clin Psychiatry; 2016 Sep; 77(9):e1137-e1143. PubMed ID: 27379563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnetic Resonance Imaging-Guided, Open-Label, High-Frequency Repetitive Transcranial Magnetic Stimulation for Adolescents with Major Depressive Disorder.
    Wall CA; Croarkin PE; Maroney-Smith MJ; Haugen LM; Baruth JM; Frye MA; Sampson SM; Port JD
    J Child Adolesc Psychopharmacol; 2016 Sep; 26(7):582-9. PubMed ID: 26849202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two Versus One High-Frequency Repetitive Transcranial Magnetic Stimulation Session per Day for Treatment-Resistant Depression: A Randomized Sham-Controlled Trial.
    Theleritis C; Sakkas P; Paparrigopoulos T; Vitoratou S; Tzavara C; Bonaccorso S; Politis A; Soldatos CR; Psarros C
    J ECT; 2017 Sep; 33(3):190-197. PubMed ID: 28072660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.